Advancing diagnostics for Chagas disease: key product characteristics and harmonized evaluation strategies - an expert meeting report
BMC Infectious Diseases·
- DOI
- 10.1186/s12879-026-13565-3
- PMID
- 42310542
- PMCID
- PMC13276932
- OpenAlex
- W7165046858
- Study type
- Guideline
- Publisher
- Springer Science and Business Media LLC
- Article type
- journal-article
- Integrity
- current
Why this research matters now
By establishing uniform evaluation criteria and mapping financial requirements, the report aims to accelerate the deployment of accessible testing instruments that align with regional elimination timelines.
Structured evidence summary
Research question
How can diagnostic pathways for Chagas disease be standardized and enhanced to increase detection and treatment coverage among affected populations?
Study design
This publication operates as a consensus guideline generated through a structured expert panel involving researchers, assay developers, and regulatory representatives.
Population and setting
The analysis focuses primarily on marginalized groups residing in Latin American regions while integrating broader international health system viewpoints.
Main findings
The panel achieved agreement on a unified assessment protocol for rapid tests, specified optimal attributes for molecular assays, and outlined necessary economic data to support clinic integration. These outputs function as a practical reference intended to guide assay development and encourage targeted funding to resolve current testing shortages.
Public-health relevance
By establishing uniform evaluation criteria and mapping financial requirements, the report aims to accelerate the deployment of accessible testing instruments that align with regional elimination timelines.
Important limitations
As a consensus-driven guideline rather than an empirical investigation, the document inherently lacks primary clinical validation data and real-world performance metrics for the proposed assessment standards.
GIDS interpretation
The manuscript establishes foundational technical and operational benchmarks for diagnostic tool assessment, offering a structured reference point for monitoring future assay development trajectories. It frames current evaluation priorities without referencing active case monitoring or commercial deployment tracking.
Related GIDS surveillance
Literature context does not validate, explain, or change a surveillance signal. Exact and contextual relationships are shown separately.
Evidence relationships
This article has 9 auditable classifier relationships to diseases, places, topics, and study design.